Acute Lymphocytic Leukemia Epidemiology Summary

Acute Lymphocytic Leukemia (ALL) Insights and Trends

• ALL accounts for approximately 22% (one-fifth) of all cancers in this age group. According to the German trial centres, about 550 to 600 children and adolescents aged 0 to 17 years are newly diagnosed with ALL in Germany each year.
• ALL accounts for approximately 80% of childhood leukemia cases, making it the most prevalent form of leukemia in children and adolescents. 
• ALL demonstrates a strong age-related pattern, with substantially better survival outcomes in pediatric patients compared with adolescents and adults, where relapse rates and treatment-related mortality remain higher.

Acute Lymphocytic Leukemia (ALL) Epidemiology Forecast in the 7MM

• 2025 Incident Cases of ALL : ~12,300
• 2036 Projected Incident Cases of ALL : ~XXX
• ALL Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Acute Lymphocytic Leukemia (ALL)– Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the ALL, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Acute Lymphocytic Leukemia (ALL) Understanding and Diagnosis Algorithm

Acute Lymphocytic Leukemia (ALL) Overview and Diagnosis

ALL is a rapidly progressing hematologic malignancy marked by the uncontrolled proliferation of immature lymphoid cells in the bone marrow, blood, and other organs. It arises from abnormal B-cell or T-cell lymphoblasts, with B-cell ALL representing most cases. Although ALL is the most common pediatric leukemia, it also affects adolescents and adults, where clinical outcomes are typically poorer. The disease is driven by several genetic abnormalities, including the Philadelphia chromosome (BCR-ABL1), which is important for prognosis and risk stratification. Common symptoms include fatigue, fever, recurrent infections, bruising, bleeding, lymphadenopathy, hepatosplenomegaly, and bone pain.

Further details are provided in the report.

Acute Lymphocytic Leukemia (ALL) Diagnosis

Diagnosis of ALL involves clinical evaluation along with hematologic, immunophenotypic, cytogenetic, and molecular assessments. Initial investigations include complete blood count (CBC) and peripheral blood smear analysis, which may reveal anemia, thrombocytopenia, leukocytosis, and circulating lymphoblasts. Definitive diagnosis is confirmed through bone marrow aspiration and biopsy demonstrating ≥20% lymphoblasts. Flow cytometry is used to classify B-cell and T-cell ALL subtypes, while cytogenetic and molecular testing help identify abnormalities such as BCR-ABL1 and other high-risk mutations. Minimal residual disease (MRD) monitoring is increasingly used for prognostic assessment and relapse risk evaluation.

Further details are provided in the report.

Acute Lymphocytic Leukemia (ALL) Epidemiology

Key Findings from Acute Lymphocytic Leukemia (ALL) Epidemiological Analysis and Forecast 

• According to DelveInsight estimates, there were approximately ~12,300 incident cases of Acute Lymphocytic Leukemia (ALL) in 2025, with nearly 58% of total cases originating from the United States.
• In the United States, individuals younger than 20 years of age accounted for the majority of Acute Lymphocytic Leukemia (ALL) cases, representing approximately 55% of the affected population in 2025.
• Amongst EU4 and the UK, Germany had highest incidence cases of Acute Lymphocytic Leukemia (ALL) i.e., ~1100. On the other hand, Spain had the lowest incident cases of Acute Lymphocytic Leukemia (ALL) in 2025.
• Among the type-specific cases of Acute Lymphocytic Leukemia (ALL) among the 7MM, the incident cases of B- Acute Lymphocytic Leukemia (ALL) accounted for nearly ~9%, while those of T- Acute Lymphocytic Leukemia (ALL) accounted for nearly ~11% in the Germany in 2025.
• SEER data reported a 5-year relative survival rate of approximately 72–73% for Acute Lymphocytic Leukemia, although survival remains significantly lower in adult and elderly patient populations compared with pediatric patients.

Scope of the Report

• The report covers a segment of a descriptive overview of Acute Lymphocytic Leukemia, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

Acute Lymphocytic Leukemia Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of Acute Lymphocytic Leukemia (ALL)? What will be the growth opportunities across the 7MM concerning the patient population with Acute Lymphocytic Leukemia (ALL)?
• What is the historical and forecasted Acute Lymphocytic Leukemia (ALL) patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.